Abstract
Introduction
The real-world evolution of management and outcomes of patients with unruptured brain
arteriovenous malformations (AVMs) has not been well-delineated following the ARUBA
trial findings of no general advantage of initial interventional (surgical/endovascular/radiotherapy)
vs. initial conservative medical therapy.
Methods
We analyzed the National Inpatient Sample from 2009-2018, capturing 20% of all admissions
in the U.S. Validated ICD-9 and -10 codes defined brain AVMs, comorbidities, and the
use of interventional modalities. Analyses were performed by year and for the dichotomized
periods of pre-ARUBA (2009-2013) vs. post-ARUBA (2014-2018).
Results
Among the national projected 88,037 AVM admissions, 72,812 (82.7%) were unruptured
AVMs and 15,225 (17.3%) were ruptured AVMs. Among uAVMs, 51.4% admitted pre-ARUBA
and 48.6% in post-ARUBA period. The post-ARUBA patients were mildly older (median
age 53.3 vs. 51.8 (p = 0.001) and had more comorbidities including hypertension, diabetes, obesity, renal
impairment, and smoking. Before the first platform report of ARUBA (2009-2012), rates
of use of interventional treatments during uAVM admissions trended up from 31.8% to
35.4%. Thereafter, they declined significantly to 26.4% in 2018 (p = 0.02). The decline was driven by a reduction in the frequency of endovascular treatment
from 18.8% to 13.9% and inpatient stereotactic radiosurgery from 0.5% to 0.1%. No
change occurred in the frequency of microsurgery or combined endovascular and surgical
approaches. Adjusted multivariable model of uAVMs showed increased odds of discharge
to a long-term inpatient facility or in-hospital death [OR 1.14 (1.02-1.28), p = 0.020] in post-ARUBA. A significantly increased proportion of ruptured AVMs from
17.0% to 23.3% was observed consistently in post-ARUBA.
Conclusion
Nationwide practice in the management of unruptured AVMs changed substantially with
the publication of the ARUBA trial in a durable and increasing manner. Fewer admissions
with the interventional treatment of unruptured AVMs occurred, and a corresponding
increase in admission for ruptured AVMs transpired, as expected with a strategy of
watchful waiting and treatment only after an index bleeding event. Further studies
are needed to determine whether these trends can be considered to be ARUBA trial effect
or are merely coincidental.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Stroke and Cerebrovascular DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Arteriovenous malformations of the brain.N Engl J Med. 2017; 376: 1859-1866
- Unruptured brain arteriovenous malformations should be treated conservatively.Stroke. 2007; 38: 3308-3309
- Unruptured brain arteriovenous malformations should be treated conservatively.Stroke. 2007; 38: 3310-3311
- Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.Lancet. 2014; 383: 614-621
- Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial.Lancet Neurol. 2020; 19: 573-581
- Responses to ARUBA: a systematic review and critical analysis for the design of future arteriovenous malformation trials.J Neurosurg. 2017; 126: 486-494
- Treatment of unruptured brain arteriovenous malformations: a single-center experience of 86 patients and a critique of the a randomized trial of unruptured brain arteriovenous malformations (ARUBA) trial.World Neurosurg. 2018; 120: e1156-e1162
- Microsurgery for unruptured cerebral arteriovenous malformations in the national inpatient sample is more common Post-ARUBA.World Neurosurg. 2020; 137: e343-e346
- Elective intervention for unruptured cranial arteriovenous malformations in relation to ARUBA trial: a National Inpatient Sample study.Acta Neurochir. 2021; 163: 2489-2495
- Effect of a randomized trial of unruptured brain arteriovenous malformation on interventional treatment rates for unruptured arteriovenous malformations.Cerebrovasc Dis. 2019; 47: 299-302
- Healthcare Cost and Utilization Project (HCUP).Agency for Healthcare Research and Quality, Rockville, MD2020
- Healthcare Cost and Utilization Project (HCUP).Agency for Healthcare Research and Quality, Rockville, MD2019
- Permutation tests for joinpoint regression with applications to cancer rates.Stat Med. 2000; 19: 335-351
- Management of brain arteriovenous malformations: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2017; 48: e200-e224
- Diffusion theory and knowledge dissemination, utilization, and integration in public health.Ann Rev Public Health. 2009; 30: 151-174
- Managing Clinical Knowledge for Health Care Improvement.2000
- Basic research and health: a reassessment of the scientific basis for the support of biomedical science.Res Eval. 2003; 12: 217-224
- Outcome after conservative management or intervention for unruptured brain arteriovenous malformations.JAMA. 2014; 311: 1661-1669
Article Info
Publication History
Published online: October 19, 2022
Accepted:
September 18,
2022
Received in revised form:
September 11,
2022
Received:
June 19,
2022
Identification
DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106807
Copyright
© 2022 Elsevier Inc. All rights reserved.
